Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …

Antibodies (Abs) containing two different antigen-binding sites in one molecule are called
bispecific. Bispecific Abs (BsAbs) were first described in the 1960s, the first monoclonal …

The development of an effective AIDS vaccine has been challenging because of viral
genetic diversity and the difficulty of generating broadly neutralizing antibodies (bnAbs). We …

The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
requires effective therapies against coronavirus disease 2019 (COVID-19), and neutralizing …

Although antiviral antibodies generally confer protective functions, antibodies against
dengue virus (DENV) are associated with enhanced disease susceptibility. Antibodies can …

Monoclonal antibodies (mAbs) that efficiently neutralize SARS-CoV-2 have been developed
at an unprecedented speed. Notwithstanding, there is a vague understanding of the various …

IgG antibodies are secreted from B cells and bind to a variety of pathogens to control
infections as well as contribute to inflammatory diseases. Many of the functions of IgGs are …

Given the absence of an effective vaccine for protection against HIV-1 infection, passive
immunization strategies that utilize potent broadly neutralizing antibodies (bnAbs) to block …

Bispecific antibodies have recently gained major interest as they allow novel mechanisms-of-
action and/or therapeutic applications that cannot be achieved using conventional IgG …

Therapeutic use of agonistic anti-CD40 antibodies is a potentially powerful approach for
activation of the immune response to eradicate tumors. However, the translation of this …